Harvard Bioscience Inc (HBIO)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $40.75M
Last updated: Nov 17, 2026 at 4:15 PM ET
Harvard Bioscience Inc (HBIO) Statistics
Harvard Bioscience (HBIO) has a market cap of $40.75M and an enterprise value of $73.04M. Its net debt of $32.30M equals 79.26% of its market cap. It kept -13.20% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 79.26% above the market cap, as debt exceeds cash.
| Market Cap | $40.75M |
|---|---|
| Enterprise Value | $73.04M |
| Latest price (Nov 17, 2026) | $9.08 |
Key Dates
| Last Earnings Date | Nov 10, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.5x and 8.1x.
| P/S Ratio | 0.5x |
|---|---|
| Forward P/S | 0.5x |
| P/B Ratio | 8.1x |
Enterprise Valuation
Counting debt and cash, the company is valued at 118.7x EBITDA.
| EV / Sales | 0.8x |
|---|---|
| EV / EBITDA | 118.7x |
Price Statistics
The stock is up 37.66% over 52 weeks and trades 8.35% above its 50-day average.
| Beta (1Y) | 1.38 |
|---|---|
| 52-Week Change | +37.66% |
| 1-Month Change | +12.24% |
| 3-Month Change | +28.25% |
| 6-Month Change | +81.24% |
| 5-Year Change | -88.18% |
| 10-Year Change | -62.92% |
| Total Return (1Y) | +37.66% |
| Total Return (3Y CAGR) | -40.35% |
| Total Return (5Y CAGR) | -34.60% |
| Return vs SPY (1Y) | +30.21% |
| Max Drawdown (1Y) | -45.24% |
| Max Drawdown (3Y) | -94.82% |
| Sharpe Ratio (1Y) | 0.48 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $8.38 |
| 200-Day Average | $6.63 |
| 52-Week Range | $4.00 to $10.20 |
| RSI (14 Days) | 56.5 |
| Average Volume (20 Days) | 30.51K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.76x current liabilities, and total debt is 7.28x shareholder equity.
| Current Ratio | 1.76x |
|---|---|
| Quick Ratio | 0.86x |
| Debt / Equity | 7.28x |
| Debt / EBITDA | 59.83x |
Returns and Efficiency
Return on invested capital is -10.25% over the last 12 months, against a 5-year average of -23.24%.
| Return on Equity (ROE) | -231.22% |
|---|---|
| Return on Assets (ROA) | -15.68% |
| Return on Invested Capital (ROIC) | -10.25% |
| Return on Capital Employed (ROCE) | -9.03% |
| ROE (5Y Average) | -90.12% |
| ROA (5Y Average) | -17.96% |
| ROIC (5Y Average) | -23.24% |
| Asset Turnover | 1.17x |
| Inventory Turnover | 1.66x |
| Receivables Turnover | 6.08x |
| Cash Conversion Cycle | 215 days |
Scores
HBIO has an Altman Z-Score of -2.50, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.50 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $89.41M over the last 12 months is up 2.34% from the 12 months before.
| Revenue | $89.41M |
|---|---|
| Revenue Growth (YoY) | +2.34% |
| Gross Profit | $51.35M |
| Operating Income | -$1.59M |
| Pretax Income | -$12.10M |
| Net Income | -$11.80M |
| EBITDA | $621.00K |
| EBIT | -$4.44M |
| Reported EPS (TTM) | -$1.79 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 6.79% of the $75.30M in total assets.
| Cash and Equivalents | $4.86M |
|---|---|
| Total Debt | $37.15M |
| Net Debt | $32.30M |
| Net Debt Per Share | $7.08 |
| Working Capital | $19.85M |
| Shareholder Equity | $5.11M |
| Book Value Per Share | $1.12 |
| Tangible Book Value | -$10.38M |
| Total Assets | $75.30M |
| Total Liabilities | $70.19M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.49M of capital spending, operating cash flow left -$3.17M of free cash flow.
| Operating Cash Flow | -$681.00K |
|---|---|
| Capital Expenditures | $2.49M |
| Free Cash Flow | -$3.17M |
| FCF Per Share | -$0.70 |
| Depreciation and Amortization | $5.53M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1.78%, against a 5-year average of -13.08%.
| Gross Margin | 57.43% |
|---|---|
| Operating Margin | -1.78% |
| Pretax Margin | -13.53% |
| Net Margin | -13.20% |
| EBITDA Margin | 0.69% |
| EBIT Margin | -4.97% |
| FCF Margin | -3.55% |
| Gross Margin (5Y Average) | 57.05% |
| Operating Margin (5Y Average) | -13.08% |
| Net Margin (5Y Average) | -18.07% |
Growth
Revenue fell 8.60% a year over 3 years.
| Revenue Growth (3Y CAGR) | -8.60% |
|---|---|
| Revenue Growth (5Y CAGR) | -3.25% |
| FCF Growth (5Y CAGR) | -7.73% |
| Book Value Per Share Growth (2Y CAGR) | -57.48% |
Dividends and Yields
HBIO does not pay a dividend. Its free cash flow yield is -7.66%.
| FCF Yield | -7.66% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-10 reverse split on Mar 16, 2026.
| Last Split Date | Mar 16, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 11 similar companies, HBIO has the 9th highest P/S.
P/S RatioPeer median 2.9x
ROICPeer median -20.19%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +3.93%
| P/S Ratio | 0.5x vs 2.9x median |
|---|---|
| ROIC | -10.25% vs -20.19% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +2.34% vs +3.93% median |
Analyst Forecast
Consensus estimates put revenue growth at 4.66% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +4.66% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HBIO
What is HBIO's market cap?
Harvard Bioscience has a market cap of $40.75M. Its enterprise value, which adds debt and subtracts cash, is $73.04M.
How many shares of HBIO are outstanding?
Harvard Bioscience has 4.56M shares outstanding. The count is up 2.36% from a year earlier.
Does HBIO pay a dividend?
No. Harvard Bioscience does not pay a dividend.
How much debt does HBIO have?
Harvard Bioscience has $37.15M of total debt and $4.86M of cash and equivalents, a net debt position of $32.30M.
HBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts